2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-170228
    c-Kit-IN-9
    Kit-IN-9 (Compound D9) is an inhibitor of c-Kit. c-Kit-IN-9 inhibits the inflammatory responses in J774A.1, RAW264.7, MPMs cells and lung tissues by blocking the activation of the NF-κB pathway induced by LPS (HY-D1056). Meanwhile, c-Kit-IN-9 exhibits good anti-inflammatory activities in acute lung injury and sepsis mouse models. c-Kit-IN-9 can be used in the research of acute lung injury and related inflammatory diseases.
    c-Kit-IN-9
  • HY-170232
    RIPK1-IN-29
    RIPK1-IN-29 (Compound 22) is a RIPK1 inhibitor, with an IC50 of 6.9 nM. RIPK1-IN-29 exerts anti-necroptotic (Apoptosis) activity by inhibiting RIPK1. In a TNF-α-induced in vivo inflammation model, at a dose of 10 mg/kg, RIPK1-IN-29 can protect mice from hypothermia and death. RIPK1-IN-29 can be applied to the research field of inflammatory diseases.
    RIPK1-IN-29
  • HY-170233
    NLRP3-IN-75
    NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models.
    NLRP3-IN-75
  • HY-17028A
    (Rac)-Besifloxacin hydrochloride 1398566-43-2
    (Rac)-Besifloxacin Hydrochloride is a fourth generation fluoroquinolone antibiotic. (Rac)-Besifloxacin Hydrochloride is a DNA gyrase and topoisomerase IV inhibitor. (Rac)-Besifloxacin Hydrochloride has broad-spectrum antibacterial activity, it is effective against Gram-negative and Gram-positive aerobic and anaerobic strains and reduces the incidence of drug resistance. (Rac)-Besifloxacin Hydrochloride has anti-inflammatory activity. Besifloxacin Hydrochloride can be used in bacterial conjunctivitis research.
    (Rac)-Besifloxacin hydrochloride
  • HY-170317
    EA-89-Succinic acid
    EA-89-Succinic acid (Compound 26) is the active control of the target protein ligand EA-89 (HY-170314), which can be used for the synthesis of PROTAC .
    EA-89-Succinic acid
  • HY-170331
    IFNα-IN-1 2700322-66-1
    IFNα-IN-1 (AJ2-18) is a IFNα inhibitor that inhibits IFN-α production. IFNα-IN-1 can be used for research of inflammation.
    IFNα-IN-1
  • HY-170364
    NLRP3-IN-60
    NLRP3-IN-60 (Compound 39) is the orally active inhibitor for NLRP3. NLRP3-IN-60 inhibits pyroptosis with an IC50 of 13 nM in THP-1 cell. NLRP3-IN-60 inhibits IL-1β release with an IC50 of 225 nM in human whole blood.
    NLRP3-IN-60
  • HY-170365
    HPK1-IN-55 3048537-58-9
    HPK1-IN-55 (compound 19) is a selective and orally active hematopoietic progenitor kinase 1 (HPK1) inhibitor with an IC50 of <0.51 nM. HPK1-IN-55 shows excellent kinase selectivity (>637-fold vs GCK-like kinase and >1022-fold vs LCK). HPK1-IN-55 has anticancer effects.
    HPK1-IN-55
  • HY-170370
    RORγt inverse agonist 34 2247604-77-7
    RORγt inverse agonist 34 (compound 5a) is a RORγt inverse agonist with an IC50 of 0.094 μM for RORγt-LBD. RORγt inverse agonist 34 is used for psoriasis research.
    RORγt inverse agonist 34
  • HY-17037S
    Pirenzepine-d8 1189944-02-2
    Pirenzepine-d8 is the deuterium labeled Pirenzepine dihydrochloride. Pirenzepine dihydrochloride (LS519) is a selective M1 muscarinic receptor antagonist.
    Pirenzepine-d8
  • HY-170396
    ABCG2-IN-4 2559759-63-4
    ABCG2-IN-4 (Compound K31) is an orally active inhibitor for ABCG2, which reduces the release of Protoporphyrin IX (PPIX) (HY-B1247) from erythrocytes into plasma, and prevents the reduces phototoxicity. ABCG2-IN-4 exhibits anti-inflammatory and antioxidant activity in mouse models.
    ABCG2-IN-4
  • HY-170397
    ADORA2A/PDE4D-IN-1 1321513-73-8
    ADORA2A/PDE4D-IN-1 (Compound 9) is a dual inhibitor for adenosine A2a receptor (ADORA2A) and phosphodiesterase 4D (PDE4D). ADORA2A/PDE4D-IN-1 can be used in research of bronchial asthma.
    ADORA2A/PDE4D-IN-1
  • HY-170409
    BNN27 1195795-81-3
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.
    BNN27
  • HY-170415
    EGR-1-IN-3 1700655-93-1
    EGR-1 IN-3 (Compound 36) is an early growth response 1 (EGR-1)-DNA binding disruptor. EGR-1-IN-3 inhibits TNFα-induced binding of EGR-1 to DNA and expression of genes associated with inflammation (such as TSLP, IL-31, IL-6 and CCL2). EGR-1-IN-3 can be used in the study of inflammatory diseases.
    EGR-1-IN-3
  • HY-170426
    DGKζ-IN-9 3062706-10-6
    DGKζ-IN-9 (compound 73) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-9
  • HY-170427
    DGKζ-IN-10 3062708-86-2
    DGKζ-IN-10 (compound 349) is a DGKζ inhibitor, with an IC50 ≤200 nM.
    DGKζ-IN-10
  • HY-17042B
    (S)-Cetirizine dihydrochloride 163837-48-7
    (S)-Cetirizine dihydrochloride ((S)-P071) is an orally active antagonist of the histamine H1 receptor with a Ki value of 39.1 nM. (S)-Cetirizine dihydrochloride exerts anti-allergic activity by binding to the histamine H1 receptor and blocking the action of histamine. (S)-Cetirizine dihydrochloride is promising for research of allergic diseases such as allergic rhinitis.
    (S)-Cetirizine dihydrochloride
  • HY-170440
    ATV2301 3049172-60-0
    ATV2301 is an orally active anti-influenza agent (EC50, H1N1 = 1.88 nM, H3N2 = 4.77 nM). ATV2301’s anti-influenza activity is due to its effects on polymerase acid protein (PA), nuclear protein (NP), and RNA-dependent RNA polymerase (RdRp).
    ATV2301
  • HY-170446
    MyD88-IN-2 3067479-71-1
    MyD88-IN-2 (compound A5S) is a Myeloid differentiation primary response 88 (MyD88) inhibitor with the Kd of 15 μM. MyD88-IN-2 shows protective effects on LPS (HY-D1056)-induced and sepsis-induced ALI mouse models.
    MyD88-IN-2
  • HY-170447
    NOD1 antagonist-2
    NOD1 antagonist-2 (compound 66) is an orally active selective antagonist of both human and mouse NOD1. NOD1 antagonist-2 (compound 66) antagonizes NOD1-induced NF-κB and MAPK pathways.
    NOD1 antagonist-2
Cat. No. Product Name / Synonyms Application Reactivity